|
The impact of the treatment was scored based on Migraine
Specific Quality of life (MSQ) Questionnaire and software
developed by GlaxoSmithKline, USA. A total of 55 chronic
migraine patients were taken for this study based on their
medical history.
The herbal supplement was administered over a period of
four months during this period the patents were asked to
fill MSQ before administrating the treatment, during the
treatment and after completion of the four months of treatment.
|
Based on the MSQ score and statically analyses, majority
of the cases showed sustained and significant improvement
in their chronic migraine symptoms and associated health-related
quality of life. No major side effects was observed or reported
during the course of study.
|